




I hereby certify that this correspondence is being deposited with the United States Postal Service on the date set forth below as First Class Mail in an envelope addressed to: Mail stop Amendment, Commissioner for Patents, P O Box 1450, Alexandria, VA 22313-1450.

Date of Signature and Deposit: August 10, 2006

  
Sara D. Vinarov

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Alan D. Attie  
Jonathan P. Stoehr  
Kathryn L. Schueler  
Susanne Michelle Clee

Date: August 10, 2006

Serial No.: 10/655,915

Group Art Unit: 1634

Filed: 09/05/2003

Examiner: Jehanne Souaya Sitton

Title: TYPE 2 DIABETES SUSCEPTIBILITY GENES File No.: 960296.99080

INFORMATION DISCLOSURE STATEMENT


Commissioner for Patents  
P O Box 1450  
Alexandria, VA 22313-1450


Dear Sir:

Enclosed are completed PTO-1449 forms listing documents, which the applicants in the above-identified application wish to bring to the attention of the Examiner for consideration in connection with the examination on the merits of this application.

A fee believed to be in the amount of \$180.00 is due in connection with this submission.

Please charge the fee to Deposit Account No. 17-0055.


  
Respectfully submitted,

  
Sara D. Vinarov  
Reg. No. 48,524  
Attorney for Applicants  
QUARLES & BRADY LLP  
P.O. Box 2113  
Madison, WI 53701-2113

TEL 608/251-5000  
FAX 608/251-9166

08/16/2006 KBERKE 00900013 170055 10655915

01 FC:1806 180.00 DA



**Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.**

Substitution for RCE 249/PTO

## **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

**(Use as many sheets as necessary)**

Sheet 1 of 2

**Complete if Known**

Application Number	10/655,915
Filing Date	09/05/2003
First Named Inventor	Alan D. Attie
Art Unit	1634
Examiner Name	Jehanne Souaya Sitton
Attorney Docket Number	960296.99080

## U. S. PATENT DOCUMENTS

## FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)			
		WO 03/027228 A2	04/03/2003	Incyte Genomics, Inc.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

*If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.*



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO

**Complete if Known**

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 2 of 2

Application Number	10/655,915
Filing Date	09/05/2003
First Named Inventor	Alan D. Attie
Art Unit	1634
Examiner Name	Jehanne Souaya Sitton
Attorney Docket Number	960296.99080

### OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		Hampe, W, et al., "The genes for the human VPS10 domain-containing receptors are large and contain many small exons," Hum Genet 108:529-536 (2001)	
		Hicke, L., "A New Ticket for Entry into Budding Vesicles-Ubiquitin," Cell 106:527530:1-4 September 7, 2001	
		Kahn, B.B., "Type 2 diabetes: when insulin secretion fails to compensate for insulin resistance, Cell 92:593-496 (1998)	
		Kahn, C.R., et al., "Genetics of non-insulin-dependent (type-II) diabetes mellitus, Annu. Rev. Med. 47:509-531 (1996)	
		Polonsky, K.S., et al, "Non-insulin-dependent diabetes mellitus: a genetically programmed failure of the beta cell ...., N Engl J Med 334:777-783 (1996)	
		Polonsky, K.S., "The beta-cell in diabetes: from molecular genetics to clinical research, Diabetes 44:705-717 (1995)	
		Stoehr, J.P., et al, "Genetic obesity Unmasks Nonlinear Interactions Between Murine Type 2 Diabetes Susceptibility Loci," Diabetes 49:1946-1954 (2000)	
		Taylor SI: Deconstructing type 2 diabetes Cell 97:9-12 (1999)	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450.. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.